We have located links that may give you full text access.
Urinary Plasminogen as a Marker of Disease Progression in Human Glomerular Disease.
American Journal of Kidney Diseases 2024 March 6
RATIONALE & OBJECTIVE: Glomerular disorders have a highly variable clinical course and biomarkers that reflect molecular mechanisms underlying progression are needed. Based on our previous work identifying plasminogen as a direct cause of podocyte injury, we designed this study to test the association between urine plasmin(ogen) (i.e., plasmin and its precursor plasminogen) and end-stage kidney disease (ESKD).
STUDY DESIGN: Multicenter cohort study.
SETTING & PARTICIPANTS: 1010 patients enrolled in the CureGN Cohort with biopsy-proven glomerular disease (focal segmental glomerulosclerosis, membranous nephropathy, and immunoglobulin A nephropathy).
PREDICTORS: The main predictor was urine plasmin(ogen) at baseline. Levels were measured by an electro-chemiluminescent immunoassay developed de novo. Traditional clinical and analytical characteristics were used for adjustment. The ratio of urine plasmin(ogen)/ expected plasmin(ogen) was evaluated as a predictor in a separate model.
OUTCOMES: Progression to ESKD.
ANALYTICAL APPROACH: Cox regression was used to examine the association between urinary plasmin(ogen) and time to ESKD. Urinary markers were Log2 transformed to approximate normal distribution and normalized to urine creatinine (Log2 uPlasminogen/Cr, Log2 urinary protein/Cr [UPCR]). Expected plasmin(ogen) was calculated by multiple linear regression.
RESULTS: Adjusted Log2 uPlasminogen/Cr was significantly associated with ESKD (HR per doubling Log2 uPlasminogen/Cr 1.31 (95% confidence interval [CI] 1.22-1.40), P < 0.001). Comparison of the predictive performance of the models including Log2uPlasminogen/Cr, Log2 UPCR or both markers showed the plasmin(ogen) model superiority. The ratio of measured/expected urine plasmin(ogen) was independently associated with ESKD, HR 0.41 (95% CI 0.22-0.77) if ratio < 0.8 and HR 2.42 (95% CI 1.54-3.78) if ratio > 1.1 (compared to ratio between 0.8-1.1).
LIMITATIONS: Single plasmin(ogen) determination does not allow for the study of changes over time. The use of a cohort of mostly white patients and the restriction to patients with 3 glomerular disorders limits the external validity of our analysis.
CONCLUSIONS: Urinary plasmin(ogen) and the ratio of measured/expected plasmin(ogen) are independently associated with ESKD in a cohort of patients with glomerular disease. Taken together with our previous experimental findings, urinary plasmin(ogen) could be a useful biomarker in prognostic decision making and a target for the development of novel therapies in patients with proteinuria and glomerular disease.
STUDY DESIGN: Multicenter cohort study.
SETTING & PARTICIPANTS: 1010 patients enrolled in the CureGN Cohort with biopsy-proven glomerular disease (focal segmental glomerulosclerosis, membranous nephropathy, and immunoglobulin A nephropathy).
PREDICTORS: The main predictor was urine plasmin(ogen) at baseline. Levels were measured by an electro-chemiluminescent immunoassay developed de novo. Traditional clinical and analytical characteristics were used for adjustment. The ratio of urine plasmin(ogen)/ expected plasmin(ogen) was evaluated as a predictor in a separate model.
OUTCOMES: Progression to ESKD.
ANALYTICAL APPROACH: Cox regression was used to examine the association between urinary plasmin(ogen) and time to ESKD. Urinary markers were Log2 transformed to approximate normal distribution and normalized to urine creatinine (Log2 uPlasminogen/Cr, Log2 urinary protein/Cr [UPCR]). Expected plasmin(ogen) was calculated by multiple linear regression.
RESULTS: Adjusted Log2 uPlasminogen/Cr was significantly associated with ESKD (HR per doubling Log2 uPlasminogen/Cr 1.31 (95% confidence interval [CI] 1.22-1.40), P < 0.001). Comparison of the predictive performance of the models including Log2uPlasminogen/Cr, Log2 UPCR or both markers showed the plasmin(ogen) model superiority. The ratio of measured/expected urine plasmin(ogen) was independently associated with ESKD, HR 0.41 (95% CI 0.22-0.77) if ratio < 0.8 and HR 2.42 (95% CI 1.54-3.78) if ratio > 1.1 (compared to ratio between 0.8-1.1).
LIMITATIONS: Single plasmin(ogen) determination does not allow for the study of changes over time. The use of a cohort of mostly white patients and the restriction to patients with 3 glomerular disorders limits the external validity of our analysis.
CONCLUSIONS: Urinary plasmin(ogen) and the ratio of measured/expected plasmin(ogen) are independently associated with ESKD in a cohort of patients with glomerular disease. Taken together with our previous experimental findings, urinary plasmin(ogen) could be a useful biomarker in prognostic decision making and a target for the development of novel therapies in patients with proteinuria and glomerular disease.
Full text links
Related Resources
Trending Papers
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: a focus on glucose control and comorbidities.Diabetologia 2024 April 17
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Eosinophilic Esophagitis: Clinical Pearls for Primary Care Providers and Gastroenterologists.Mayo Clinic Proceedings 2024 April
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app